Bayer says 2024 sales of prostate cancer drug above $1 bln
FRANKFURT, March 21 (Reuters) – Bayer (BAYGn.DE) on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker’s growth prospects after the failure of a promising anti-blood-clotting therapy.
“Nubeqa … is set for continued growth in prostate cancer and is on track to reach blockbuster status this year – only five years after first indication launch,” it said in a statement.
Blockbuster is an industry term for drugs with at least $1 billion in annual sales.
Bayer chalked up sales of Nubeqa, jointly developed with Finnish drugmaker Orion (ORNBV.HE), of 869 million euros ($948 million) last year and the company has previously projected annual peak sales potential of more than three billion euros.